MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
8.93
-0.33 (-3.56%)
Oct 29, 2025, 4:00 PM EDT - Market closed
MeiraGTx Holdings Employees
As of December 31, 2024, MeiraGTx Holdings had 381 total employees, including 375 full-time and 6 part-time employees. The number of employees decreased by 44 or -10.35% compared to the previous year.
Employees
381
Change (1Y)
-44
Growth (1Y)
-10.35%
Revenue / Employee
$99,520
Profits / Employee
-$413,399
Market Cap
718.40M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 381 | -44 | -10.35% |
| Dec 31, 2023 | 425 | 67 | 18.72% |
| Dec 31, 2022 | 358 | 62 | 20.95% |
| Dec 31, 2021 | 296 | 77 | 35.16% |
| Dec 31, 2020 | 219 | 62 | 39.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MGTX News
- 22 days ago - MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress - GlobeNewsWire
- 5 weeks ago - MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital - Seeking Alpha
- 2 months ago - MeiraGTx Reports Second Quarter 2025 Financial and Operational Results - GlobeNewsWire
- 6 months ago - MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting - GlobeNewsWire
- 6 months ago - MeiraGTx Reports First Quarter 2025 Financial and Operational Results - GlobeNewsWire
- 6 months ago - MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease - GlobeNewsWire
- 6 months ago - Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more - GlobeNewsWire
- 7 months ago - MeiraGTx Holdings: Gaining Regulatory Focus - Seeking Alpha